[Results of 30 days and 12 months treatment with salmeterol in patients with asthma and COPD].
148 outpatients with asthma and COPD were treated with inhaled steroids and salmeterol. 48 patients were estimated after 30 days treatment and other 100, who accepted salmeterol after 1 year treating. In these two groups of patients inhalations of other beta-mimethics, dyspnoe during the nights and early mornings, change of FEV1, side effects and acceptation of salmeterol were observed. After 1 months of treatment in 45% and after 1 year in 73% increase of FEV1 were noticed. In asthma group in 66% and in 15% COPD patients increase of MEV50 was observed. After 30 days 22% asthma patients and 30% COPD patients did not accept salmeterol. 6 persons had adverse effects/tachycardia, sore throat, exacerbation of dyspnoe/. After 12 months 87% accepted treatment with salmeterol. In 13 cases therapy with salmeterol was stopped, because results were poor.
Droszcz
P
P
Katedry i Kliniki Chorób Wewnetrznych i Pneumonologii Akademii Medycznej w Warszawie.
Droszcz
W
W
D000318:Adrenergic beta-Agonists / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068299:Salmeterol Xinafoate; D013997:Time Factors; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D000068299:Salmeterol Xinafoate; D000420:Albuterol
Wyniki 30-dniowego i 12-miesiecznego leczenia salmeterolem chorych na astme i przewlekła obturacyjna chorobe płuc.